Telix, GMS & Monash Awarded $23 million Federal Funding
Filed with ASX · · 3 pages · English
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Commercial Launch - Illuccix Now Available to Order in US
- FDA Orphan Drug Designation for Bone Marrow Conditioning
- Telix and Xiel Sign U.K. and Ireland Distribution Agreement
- Development of Glioblastoma Therapy Program
- Radiopharmaceutical Production Facility Buildout Commences
Later from Telix Pharmaceuticals
- Telix Enters Licence Agreement with Lilly for Olaratumab
- ProstACT TARGET Phase II Study Ethics Approval
- Appendix 4C and Activities Report for March 2022 quarter
- Illuccix Reimbursement Milestone and Launch Updates
- Leadership changes including Darren Smith appointment as CFO
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals